WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series, No. 885 - Thirty-fifth Report
(1999; 168 pages) [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoWHO Expert Committee on Specifications for Pharmaceutical Preparations
Ver el documento1. Introduction
Abrir esta carpeta y ver su contenido2. The international pharmacopoeia and related issues
Abrir esta carpeta y ver su contenido3. International Chemical Reference Substances and Infrared Reference Spectra
Abrir esta carpeta y ver su contenido4. Quality control - national laboratories
Abrir esta carpeta y ver su contenido5. Good manufacturing practices
Abrir esta carpeta y ver su contenido6. Quality systems and inspection
Abrir esta carpeta y ver su contenido7. Other quality assurance topics
Abrir esta carpeta y ver su contenido8. Nomenclature and terminology
Abrir esta carpeta y ver su contenido9. Legal aspects of pharmaceuticals
Abrir esta carpeta y ver su contenido10. Regulatory issues
Abrir esta carpeta y ver su contenido11. Training activities
Ver el documento12. Pharmaceuticals contaminated with diethylene glycol
Ver el documentoAcknowledgements
Ver el documentoReferences
Ver el documentoAnnex 1. List of available International Chemical Reference Substances1
Ver el documentoAnnex 2. List of available International Infrared Reference Spectra1
Abrir esta carpeta y ver su contenidoAnnex 3. General guidelines for the establishment, maintenance and distribution of chemical reference substances
Abrir esta carpeta y ver su contenidoAnnex 4. Good manufacturing practices: authorized person - role, functions and training
Abrir esta carpeta y ver su contenidoAnnex 5. Good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients
Abrir esta carpeta y ver su contenidoAnnex 6. Guidelines for inspection of drug distribution channels
Ver el documentoAnnex 7. Good pharmacy practice in community and hospital pharmacy settings
Abrir esta carpeta y ver su contenidoAnnex 8. National drug regulatory legislation: guiding principles for small drug regulatory authorities
Cerrar esta carpetaAnnex 9. Provisional guidelines for developing training programmes: inspection and examination of counterfeit pharmaceuticals
Cerrar esta carpeta1. General remarks
Ver el documento1.1 Introduction
Ver el documento1.2 Requirements and goals of the training programmes for inspection and examination
Ver el documento1.3 Prerequisites
Abrir esta carpeta y ver su contenido2. Training programme for inspection
Abrir esta carpeta y ver su contenido3. Training programme on examination
Ver el documentoReferences
Ver el documentoWorld Health Assembly resolutions
Ver el documentoAppendix 1 The practical issues of organizing and implementing the programme
Ver el documentoAppendix 2 Thin-layer chromatography and its application
Ver el documentoWorld Health Organization Technical Report Series
Ver el documentoSelected WHO Publications of Related Interest
Ver el documentoBack Cover
 

1.2 Requirements and goals of the training programmes for inspection and examination

The requirements for the programme may be defined by the fact that an effective approach to the detection and prevention of counterfeit pharmaceuticals requires professional competence of the personnel, motivation, and awareness of the problems.

The ultimate goals of the programme should be:

- to raise the morale of professionals involved in drug inspection and examination;

 

- to establish a control system to prevent the flow of counterfeit pharmaceuticals into the legitimate distribution channel.

 

These goals cannot be achieved without the concerted effort of other programmes concerned with improvement of the pharmaceutical infrastructure. In order to ensure the quality, safety and efficacy of drug products accessible to the target population, a secured and satisfactory drug distribution system is required.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013